Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$33.89 USD
+1.62 (5.02%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $33.89 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TARS 33.89 +1.62(5.02%)
Will TARS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
Other News for TARS
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in ITeos Therapeutics Inc
Tarsus Pharmaceuticals management to meet with Oppenheimer
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Singular Genomics Systems Inc